Third-line therapy in metastatic renal cell carcinoma: Results from the International mRCC Database Consortium.
Daniel Yick Chin Heng(University of Calgary), Toni K. Choueiri(Harvard University), Connor Wells(Queen Mary University of London), Ravindran Kanesvaran(University of Ioannina), Sumanta K. Pal(City of Hope), Ajjai Alva(Michigan Medicine), Aristotelis Bamias(National and Kapodistrian University of Athens), Frede Donskov(Aarhus University Hospital), Georg A. Bjarnason(Sunnybrook Health Science Centre), Brian I. Rini(Vanderbilt University Medical Center), Jennifer J. Knox(National Cancer Center), D. Scott Ernst, Lori Wood(Dalhousie University), Martin Smoragiewicz(University of Cambridge), Takeshi Yuasa(Japanese Foundation For Cancer Research), Haru Yamamoto(University of California, Berkeley), Sandy Srinivas(Stanford University), Reuben Broom(Auckland City Hospital), Jae‐Lyun Lee(Ulsan College), Benoit Beuselinck(Universitair Ziekenhuis Leuven)
Cited by 6
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k